CLINICAL TRIALS PROFILE FOR TAPENTADOL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for tapentadol hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00361504 ↗ | A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain | Completed | Grünenthal GmbH | Phase 3 | 2006-11-01 | The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back pain, or pain caused by knee or hip osteoarthritis. |
| NCT00361504 ↗ | A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2006-11-01 | The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back pain, or pain caused by knee or hip osteoarthritis. |
| NCT00361582 ↗ | A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery | Completed | Grünenthal GmbH | Phase 3 | 2006-10-01 | The purpose of this study is to evaluate in patients who are eligible for elective primary total or partial joint replacement of the hip or knee due to chronic osteoarthritis the efficacy (level of pain control) of CG5503 over 5 and 10 days compared with placebo, and to assess the safety and tolerability of multiple doses of CG5503 IR patients. |
| NCT00361582 ↗ | A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2006-10-01 | The purpose of this study is to evaluate in patients who are eligible for elective primary total or partial joint replacement of the hip or knee due to chronic osteoarthritis the efficacy (level of pain control) of CG5503 over 5 and 10 days compared with placebo, and to assess the safety and tolerability of multiple doses of CG5503 IR patients. |
| NCT00364247 ↗ | A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo Followed by a Voluntary Open Label Extension for Safety. | Completed | Grünenthal GmbH | Phase 3 | 1969-12-31 | The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of the administration of 3 different dose levels of CG5503 compared with oxycodone and with placebo in patients who have had a bunionectomy, and to assess the safety of the drug for 9 days after patients are discharged from the hospital. |
| NCT00364247 ↗ | A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo Followed by a Voluntary Open Label Extension for Safety. | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 1969-12-31 | The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of the administration of 3 different dose levels of CG5503 compared with oxycodone and with placebo in patients who have had a bunionectomy, and to assess the safety of the drug for 9 days after patients are discharged from the hospital. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for tapentadol hydrochloride
Condition Name
Clinical Trial Locations for tapentadol hydrochloride
Trials by Country
Clinical Trial Progress for tapentadol hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for tapentadol hydrochloride
Sponsor Name
